NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Abingworth Management’

26 February 2014

Abingworth closes sixth fund above target

life science test tube_sq UK life sciences-focused firm Abingworth Management is reportedly nearing a final close for its sixth fund, which has been oversubscribed.

22 January 2014

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

dna Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

dna RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014